Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer

被引：5
|
作者：
McNamara, Blair [1 ]
Chang, Yifan [1 ]
Mutlu, Levent [1 ]
Harold, Justin [1 ]
Santin, Alessandro D. [1 ]
机构：
[1] Yale Univ, Dept Obstet Gynecol & Reprod Sci, Sch Med, 333 Cedar St,LSOG 305,POB 208063, New Haven, CT 06520 USA
来源：
EXPERT OPINION ON BIOLOGICAL THERAPY | 2023年 / 23卷 / 03期
关键词：
Cervical cancer; immune checkpoint inhibitor; PD-1; pembrolizumab; bevacizumab; HUMAN-PAPILLOMAVIRUS; MONOCLONAL-ANTIBODY; INTRAEPITHELIAL NEOPLASIA; EXPRESSION; EFFICACY; SAFETY; WOMEN; ANGIOGENESIS; STIMULATION; STATISTICS;
D O I：
10.1080/14712598.2023.2182679
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
IntroductionDespite progress on prevention and treatment of cervical cancer, global morbidity and mortality remain high. Immunotherapy, in conjunction with standard chemotherapy, presents an opportunity for further benefit.Areas coveredHere we report the pharmacologic properties, evidence for clinical efficacy, safety, and tolerability of pembrolizumab in addition to standard chemotherapy with and without bevacizumab for treatment of advanced or recurrent cervical cancer.Expert opinionIn patients with progressive, recurrent, or metastatic PD-L1 expressing cervical cancer, without contraindication to anti-VEGF therapy, the use of pembrolizumab with bevacizumab and standard chemotherapy with carboplatin and paclitaxel is warranted. There is no evidence to support the use of pembrolizumab for this population broadly, and no evidence to support its use in PD-L1 non-expressing tumors.
引用
收藏
页码：227 / 233
页数：7
相关论文
共 50 条
  • [1] Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
    Colombo, Nicoletta
    Dubot, Coraline
    Lorusso, Domenica
    Caceres, M. Valeria
    Hasegawa, Kosei
    Shapira-Frommer, Ronnie
    Tewari, Krishnansu S.
    Salman, Pamela
    Usta, Edwin Hoyos
    Yanez, Eduardo
    Gumus, Mahmut
    de Mendoza, Mivael Olivera Hurtado
    Samouelian, Vanessa
    Castonguay, Vincent
    Arkhipov, Alexander
    Toker, Sarper
    Li, Kan
    Keefe, Stephen M.
    Monk, Bradley J.
    [J]. OBSTETRICAL & GYNECOLOGICAL SURVEY, 2022, 77 (01) : 30 - 31
  • [2] Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
    Colombo, N.
    Dubot, C.
    Lorusso, D.
    Caceres, M., V
    Hasegawa, K.
    Shapira-Frommer, R.
    Tewari, K. S.
    Salman, P.
    Usta, E. Hoyos
    Yanez, E.
    Gumus, M.
    de Mendoza, M. Olivera Hurtado
    Samouelian, V
    Castonguay, V
    Arkhipov, A.
    Toker, S.
    Li, K.
    Keefe, S. M.
    Monk, B. J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (20): : 1856 - 1867
  • [3] Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis
    Barrington, David A.
    Riedinger, Courtney
    Haight, Paulina J.
    Tubbs, Crystal
    Cohn, David E.
    [J]. GYNECOLOGIC ONCOLOGY, 2022, 165 (03) : 500 - 505
  • [4] Bevacizumab plus chemotherapy versus combination chemotherapy only in metastatic, recurrent, and persistent cervical cancer
    Choi, H.
    Kim, B. G.
    Lee, Y. Y.
    [J]. GYNECOLOGIC ONCOLOGY, 2019, 154 : 275 - 275
  • [5] Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer
    Choi, Hyun-Jin
    Lee, Yoo-Young
    Choi, Chel Hun
    Kim, Tae-Joong
    Lee, Jeong-Won
    Bae, Ji Hye
    Bae, Duk-Soo
    Kim, Byoung-Gie
    [J]. CURRENT PROBLEMS IN CANCER, 2020, 44 (05)
  • [6] FISTULAE IN WOMEN TREATED WITH CHEMOTHERAPY WITH AND WITHOUT BEVACIZUMAB FOR PERSISTENT, RECURRENT OR METASTATIC CERVICAL CANCER IN GOG-240
    Willmott, L. J.
    Java, J. J.
    Monk, B. J.
    Shah, J.
    Husain, A.
    Tewari, K. S.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 29 - 29
  • [7] Bevacizumab in Metastatic, Recurrent, or Persistent Cervical Cancer The BC Cancer Experience
    Tinker, Anna V.
    Fiorino, Leathia
    O'Dwyer, Helena
    Kumar, Aalok
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (08) : 1592 - 1599
  • [8] Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer
    Eskander, Ramez N.
    Tewari, Krishnansu S.
    [J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2014, 26 (04) : 314 - 321
  • [9] Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent, or metastatic cervical cancer: KEYNOTE-826
    Yonemori, Kan
    Nishio, Shin
    Usami, Tomoka
    Minobe, Shinichiro
    Yunokawa, Mayu
    Iwata, Takashi
    Okamoto, Aikou
    Aoki, Yoichi
    Itamochi, Hiroaki
    Takekuma, Munetaka
    Harano, Kenichi
    Yamamoto, Keiko
    Ugai, Hiroyuki
    Tekin, Cumhur
    Toker, Sarper
    Colombo, Nicoletta
    Fujiwara, Keiichi
    Hasegawa, Kosei
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S476 - S476
  • [10] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB plus CHEMOTHERAPY FOR PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER IN JAPAN
    Akai, M.
    Moriwaki, K.
    Morimoto, K.
    Shimozuma, K.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S69 - S69
12345